Reduced NGF secretion by HT-29 human colon cancer...

Reduced NGF secretion by HT-29 human colon cancer cells treated with a GRPR antagonist.

Abstract

The gastrin-releasing peptide receptor (GRPR) is a therapeutic target in colon cancer. Here we show that the GRPR antagonist RC-3095 (10(-3), 10(-6), or 1 microM) decreases nerve growth factor (NGF) secretion measured by enzyme-linked immunosorbent assay (ELISA) in HT-29 human colon carcinoma cells. The results suggest that decreased secretion of neurotrophins might be a novel mechanism by which GRPR antagonists exert their antiproliferative effects in cancer cells.

Authors

de Farias CB; Stertz L; Lima RC; Kapczinski F; Schwartsmann G; Roesler R

Journal

Protein and Peptide Letters, Vol. 16, No. 6, pp. 650–652

Publisher

Bentham Science Publishers

Publication Date

June 1, 2009

DOI

10.2174/092986609788490177

ISSN

0929-8665

Associated Experts

Flavio Kapczinski

Professor Emeritus, Faculty of Health Sciences

Visit profile

Labels